Neuroimaging Core

项目摘要-神经成像核心(NIC) IADRC的NIC将作为区域和国家的老龄化和神经变性资源 通过提供对高级应用程序的访问和协作支持， 临床和转译研究中的神经成像。网络接口卡在开发和 实施神经成像和成像遗传学分析中的尖端方案和技术， 与NIA资助的计划(如ADNI、DIAN、ADGC等)合作，并在以下方面提供培训 为所有层次和学科的科学家提供神经成像和成像遗传学。在此应用程序中，网卡将 追求以下具体目标：(1)支持IADRC、IU老龄研究中心、 以及目前采用或可能受益于高级神经成像的相关计划；(2)提供 标准化、最先进的神经成像采集和分析方案；(3)扩展跨学科 区域神经科学研究使用先进的神经成像工具来研究疾病机制和 神经退行性变的治疗；(4)支持与主要国家和国际AD相关的合作 使用神经成像和遗传学方法的研究联盟；(5)提供跨学科教育 阿尔茨海默病和其他退行性疾病的基础和临床神经影像和遗传学机会 各级科学家，从本科生到博士后研究员和教职员工，以及传播 将神经成像结果带给社区。NIC与临床核心密切合作，将执行 最先进的多模式磁共振成像(西门子Prisma 3T：高分辨率结构，3D pCASL灌注，多波段静息- 基于状态和任务的功能磁共振成像，以及针对结构和功能连接体优化的混合扩散和DTI 分析)所有符合条件的IADRC参与者，以及&gt；200 IADRC参与者的淀粉样蛋白和/或tau PET。 处于临床前或早期症状阶段的参与者(例如，主观认知下降或轻度认知 损害)、迟发性阿尔茨海默病和来自导致痴呆的突变家庭的个人 按优先顺序排列。如果有影像-病理对照，将提高对早期结构、 体内观察到的功能和分子变化，可能有助于确定新的治疗靶点。克罗斯- 与ADNI、DIAN和其他公司一起进行的形态图像分析和成像遗传学研究的结果将有助于 作为动态生物标志物的早期检测、机制理解和优化成像的进展 研究治疗效果。获取标准化的最先进的MRI和PET数据，供许多人使用 研究人员将提高研究效率并促进定量分析。与其他内核集成 将使IADRC能够通过将成像生物标记物与神经心理学联系起来来扩展这些分析 测量、神经病理样本、遗传和其他组学标记。网卡将继续促进和 通过地方、地区和国家/国际合作支持先进的成像研究。网卡 将推进AD成像研究，以实现国家适应行动方案到2025年有效预防和治疗AD的目标。

Project Summary – Neuroimaging Core (NIC) The NIC of the IADRC will serve as a regional and national resource for the aging and neurodegeneration research community by providing access to, and collaborative support for, the application of advanced neuroimaging in clinical and translational research. The NIC has been productive in developing and implementing cutting-edge protocols and techniques in neuroimaging and imaging genetics analysis, collaborating with NIA-funded initiatives (e.g., ADNI, DIAN, ADGC, etc.), and in providing training in neuroimaging and imaging genetics to scientists of all levels and disciplines. In this application, the NIC will pursue the following specific aims: (1) Support funded research in the IADRC, IU Center for Aging Research, and related programs that currently employ or could benefit from advanced neuroimaging; (2) Provide standardized, state-of-the-art neuroimaging acquisition and analysis protocols; (3) Expand transdisciplinary regional neuroscience research using advanced neuroimaging tools to study disease mechanisms and treatments for neurodegeneration; (4) Support and collaborate with major national and international AD-related research consortia using neuroimaging and genetics methods; (5) Provide transdisciplinary educational opportunities in neuroimaging and genetics of AD and other degenerative disorders for basic and clinical scientists at all levels from undergraduates to post-doctoral fellows and faculty, as well as dissemination of neuroimaging results to the community. The NIC, working closely with the Clinical Core, will perform state-of- the-art multimodal MRI (Siemens Prisma 3T: high resolution structural, 3D pCASL perfusion, multiband resting- state and task-based fMRI, and hybrid diffusion and DTI optimized for structural and functional connectome analysis) on all eligible IADRC participants, as well as amyloid and/or tau PET on >200 IADRC participants. Participants in preclinical or early symptomatic phases (e.g., subjective cognitive decline or mild cognitive impairment), late-onset AD, and individuals from families with mutations causal for dementias will be prioritized. Imaging-pathologic correlation when available will improve the understanding of early structural, functional, and molecular changes observed in vivo and may help identify novel therapeutic targets. Cross- modality image analyses and results of imaging genetics studies with ADNI, DIAN, and others will contribute to advances in early detection, mechanistic understanding, and optimize imaging as a dynamic biomarker to study therapeutic effects. Acquiring standardized state-of-the-art MRI and PET data for use by many investigators will increase research productivity and facilitate quantitative analyses. Integration with other cores will allow the IADRC to expand on these analyses by relating imaging biomarkers to neuropsychological measures, neuropathologic samples, genetic and other –omics markers. The NIC will continue to foster and support advanced imaging research through local, regional, and national/international collaborations. The NIC will advance AD imaging research to meet the goal of NAPA for preventing and effectively treating AD by 2025.